Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

Canada - English - Health Canada

agila jamp canada inc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg;   - capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg   excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg;   - capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg   excipient: gelatin iron oxide red macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg;   - capsule - 80 mg - active: vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg   excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.